RSCM
ALLO icon

Rock Springs Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Rock Springs Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-440,468
Closed -$18.9M – 149
2020
Q2 		$18.9M Buy
440,468
+190,468
+76% +$6.89M 0.52% 64
2020
Q1 		$4.86M Buy
+250,000
New +$5.95M 0.2% 100

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Rock Springs Capital Management's ALLO Position: Q3 2020 in Review

Rock Springs Capital Management sold out of Allogene Therapeutics (ALLO) in Q3 2020, closing a stake of 440,468 shares — an estimated $18.9M sold.

Rock Springs Capital Management first reported a position in ALLO in Q1 2020 and held it in 2 quarters. The position peaked at $18.9M in Q2 2020. 162 funds tracked by Wall St. Rank hold ALLO as of Q3 2020.

  • Rock Springs Capital Management reported no remaining Allogene Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Rock Springs Capital Management sold 440,468 Allogene Therapeutics shares in Q3 2020, an estimated $18.9M.
  • Rock Springs Capital Management first reported a position in Allogene Therapeutics in Q1 2020 and held it in 2 quarters.
  • Rock Springs Capital Management's Allogene Therapeutics position peaked at $18.9M in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2020.

Based on Rock Springs Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.